Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

hed that starting with cohort 2, PCI-32765 fully occupied the target kinase. Examining response in fully occupied dose cohorts the response rate ("RR") was 56% in the evaluable patient population and 48% in the ITT patient population. Including disease control in the form of stable disease in our assessment of evaluable patients, the disease control rate was 78% (10% CRs, 41% PRs and 27% SDs). Of note, the median tumor reduction from base line in our objective responding patients was 75% as of August 31, 2010.  
  • As of August 31, 2010, 23 patients continue to remain on study. This compares with 25 patients on study as of the ASCO presentation on June 4, 2010.  Median duration of response has not yet been determined in this ongoing study. The company has submitted an abstract describing the duration of response to the American Society of Hematology (ASH) in Orlando, FL on December 4-7, 2010; consistent with ASH's guidelines, we will not be disclosing these data prior to our ASH presentation.
  • PCI-32765 appears to be well tolerated through the initial exposure even in its highest dosing cohort (including 12.5 mg/kg). Only 2 patients of the enrolled 47 patients have experienced a dose limiting toxicity (DLT) on this trial (drug hypersensitivity and delay in dosing due to neutropenia for 7 days). No other DLTs have been observed. Thirteen of the 47 patients had 1 or more serious adverse events, but only 2 were considered drug related by investigators.
  • As previously announced we have initiated a Phase Ib trial in CLL/SLL patients studying 2 populations. One population is relapsed or refractory patients at 420 mg (24 patients with fixed dosing). The second population is elderly naive patients at 420 mg (12 patients with fixed dosing). Enrollment commenced end of May and as of to date we have dosed 30 patients (22/24 in the 420 mg relapsed or refractory dosed arm and 8/12 elderly naive patients). Amongst all patients dosed we maintain a ben
    '/>"/>

  • SOURCE Pharmacyclics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
    2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
    3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
    4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
    5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
    6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
    7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
    8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
    9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
    10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
    11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... , Sept. 2, 2014 Particle Sciences, ... to its investment in development and manufacturing capabilities with ... Karl Mueller , Particle Sciences, Associate Director Clinical ... pace adding clean room square footage, equipment and staff ... clients.  The company now has over 6000ft 2 ...
    (Date:9/2/2014)... Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® Corporation (ODEV) ... Stem, the latest addition to its growing hip ... intended for use in total hip arthroplasty and ... Alpine was developed based ... ODEV,s engineers worked closely with a select team ...
    (Date:9/2/2014)... NEW YORK , September 2, 2014 ... regarding WellPoint Inc. (NYSE: WLP ), Tekmira ... (NYSE: ZTS ), Sanofi SA (NYSE: ... wealth members receive these notes ahead of publication. To ... http://www.analystsreview.com/6142-100free . , ,-- ,WellPoint Inc. Research Reports ,WellPoint ...
    Breaking Medicine Technology:Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Ortho Development Receives FDA Clearance for Alpine Hip Stem 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6
    (Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
    (Date:9/2/2014)... (PRWEB) September 02, 2014 The use ... blood thinners is growing at a rapid pace, even ... mount in courts around the U.S., Bernstein Liebhard LLP ... Journal of Medicine, within a year of its 2011 ... Xarelto as warfarin, a blood thinner that has been ...
    (Date:9/2/2014)... News) -- Complications are rare among breast cancer ... study indicates. However, the researchers did find ... slightly higher risk for certain complications than a ... 18,000 breast cancer patients who had a single ... reconstruction and were followed for 30 days after ...
    (Date:9/2/2014)... a large population-based study of randomly selected participants ... (MCI) occurred twice more often in individuals diagnosed ... association was only observed in middle-aged participants (50-65 ... association vanished. This study is published in the ... concept of MCI describes an intermediate state between ...
    (Date:9/2/2014)... Medex Analytic Services is delighted ... in Coral Springs, Fla. due to their greater than ... objectives for the 2014 year by distinguishing Medex in ... requested a higher level of service and professionalism in ... and the industry has responded.” , The location of ...
    Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2
    ... known that diabetes, one of the world’s leading debilitating diseases, ... 194 million adults worldwide. Therefore, there is a huge demand ... the patients. ,There are two types of diabetes: ... for approximately 5% of all the cases. This type is ...
    ... been used by a pediatric research team to scrutinize ... small defects that lead to genetic diseases //. ... detect these abnormalities, the new research may lead to ... that lead to mental retardation. ,“For years, ...
    ... in Australia have been linked to the work place each ... //and the University of Sydney has shown that about 1,600 ... asbestos, passive smoking, fumes and exhaust at work. Several cases ... a work related origin. ,Professor Lin Fritschi, lead ...
    ... are planning to demand the government to levy heavy tax ... mainly combat the nation's obesity epidemic. The issue mainly addresses ... of salt added to burgers and processed foods. The ... to obesity. Due to this the sales of soft drinks ...
    ... CHICAGO - Abnormal glucose metabolism, which occurs when the ... twice as common among patients //with chronic nerve dysfunction ... may be a risk factor for the condition, according ... in the August 2006 print issue of Archives of ...
    ... have left its impact on the six million care givers in ... because of caring //. ,The survey revealed that only ... GP while 90% of them considered that they should be offered ... that their own health problems affected their ability to care. Besides ...
    Cached Medicine News:Health News:Inhaled Insulin: A New Modality for Management of Diabetes 2Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 2Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 3Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 4Health News:Work Related Cancer on the Rise in Australia 2Health News:Abnormal Glucose Metabolism May Contribute to Chronic Nerve Disorder 2Health News:Care Workers Need Some Care Too 2
    ... Sterilized Diamond Tips are available as ... Tips are irradiated by gamma-rays for more ... certificate of sterilization, specifying the date of ... usepractical, no need to autoclave. SterilPack Diamond ...
    This ultra micro tip for the Eppendorf and Nichiryo/BenchMate 0.5-10 L pipettors is perfect for working with low volume....
    ... way to order tips. Each box contains 1000 ... which contains 200 tips (4 bags of 50 ... of 200 tips per pack. Bulk Packs are ... be opened for quick access to Gilsons Diamond ...
    ... Finntips have been designed to optimize ... quality of our tip products is widely ... Finntip range has been extended over the ... of standard and special tips including filter ...
    Medicine Products: